Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20230357255
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 9, 2023
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20230338389
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 26, 2023
    Publication date: October 26, 2023
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 11795166
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: October 24, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11787793
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 17, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 11780840
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Tricyclic pyridone compounds as JAK2 V617F inhibitors
    Patent number: 11767323
    Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: September 26, 2023
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
  • Bicyclic dione compounds as inhibitors of KRAS
    Patent number: 11767320
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: September 26, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Taisheng Huang, Xiaozhao Wang, Wenqing Yao
  • Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
    Patent number: 11753413
    Abstract: The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 12, 2023
    Assignee: Incyte Corporation
    Inventors: Zhiyong Yu, Liangxing Wu, Wenqing Yao
  • Fused pyrimidine compounds as KRAS inhibitors
    Patent number: 11739102
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: August 29, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Gia Hoang, Xiaozhao Wang, Wenqing Yao
  • Carboxamide compounds and uses thereof
    Patent number: 11731958
    Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 22, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11718605
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: August 8, 2023
    Assignee: Incyte Corporation
    Inventors: Zhiyong Yu, Liangxing Wu, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 11713317
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: August 1, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230226062
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 26, 2022
    Publication date: July 20, 2023
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
    Publication number: 20230226040
    Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
    Type: Application
    Filed: November 21, 2022
    Publication date: July 20, 2023
    Inventors: Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
  • Naphthyridinone compounds as JAK2 V617F inhibitors
    Patent number: 11691971
    Abstract: The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: July 4, 2023
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
  • SPIRO COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230192696
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Le ZHAO, Xiaozhao WANG, Wenyu ZHU, Haolin YIN, Liangxing WU, Wenqing YAO
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230192689
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11673883
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
    Patent number: 11673894
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230174555
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: August 30, 2022
    Publication date: June 8, 2023
    Inventors: Gencheng Li, Haolin Yin, Chao Qi, Xiaozhao Wang, Wenqing Yao, Bin Hu, Peter Carlsen